Alfredo Addeo

7.3k total citations · 2 hit papers
191 papers, 3.5k citations indexed

About

Alfredo Addeo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Alfredo Addeo has authored 191 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Oncology, 117 papers in Pulmonary and Respiratory Medicine and 32 papers in Molecular Biology. Recurrent topics in Alfredo Addeo's work include Lung Cancer Treatments and Mutations (89 papers), Cancer Immunotherapy and Biomarkers (53 papers) and Lung Cancer Research Studies (46 papers). Alfredo Addeo is often cited by papers focused on Lung Cancer Treatments and Mutations (89 papers), Cancer Immunotherapy and Biomarkers (53 papers) and Lung Cancer Research Studies (46 papers). Alfredo Addeo collaborates with scholars based in Switzerland, Italy and United Kingdom. Alfredo Addeo's co-authors include Alex Friedlaender, Giuseppe Luigi Banna, Glen J. Weiss, Umberto Malapelle, Maxime Borgeaud, Vivek Subbiah, Giulio Metro, Solange Peters, Alessandro Russo and Michel Obéid and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Alfredo Addeo

178 papers receiving 3.4k citations

Hit Papers

Oncogenic driver mutations in non-small cell lung cancer:... 2021 2026 2022 2024 2021 2024 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
    2021 157 citations Maxime Borgeaud, Alfredo Addeo et al. profile →
  2. Oncogenic alterations in advanced NSCLC: a molecular super-highway
    2024 47 citations Alex Friedlaender, Giuseppe Luigi Banna et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alfredo Addeo Switzerland 34 2.2k 1.6k 860 550 379 191 3.5k
Renato Martins United States 24 2.6k 1.2× 1.7k 1.1× 811 0.9× 445 0.8× 436 1.2× 81 4.0k
Ishmael Jaiyesimi United States 21 1.3k 0.6× 784 0.5× 632 0.7× 537 1.0× 267 0.7× 119 3.1k
Raghav Sundar Singapore 31 1.7k 0.8× 769 0.5× 811 0.9× 342 0.6× 390 1.0× 141 3.2k
Darragh Halpenny United States 23 2.2k 1.0× 1.5k 0.9× 703 0.8× 331 0.6× 349 0.9× 82 3.7k
Bhawna Sirohi India 33 1.7k 0.8× 792 0.5× 817 0.9× 514 0.9× 325 0.9× 171 3.8k
Alan H. Bryce United States 26 1.0k 0.5× 1.3k 0.8× 642 0.7× 545 1.0× 199 0.5× 167 2.5k
Yuanyuan Zhao China 29 1.9k 0.8× 1.1k 0.7× 558 0.6× 533 1.0× 273 0.7× 162 3.0k
Kerry L. Reynolds United States 36 3.7k 1.7× 1.2k 0.7× 581 0.7× 315 0.6× 727 1.9× 153 5.0k
Sercan Aksoy Türkiye 27 1.7k 0.8× 780 0.5× 554 0.6× 430 0.8× 274 0.7× 284 3.6k
Bruno V. Sinn Germany 27 1.6k 0.7× 523 0.3× 950 1.1× 1.2k 2.1× 342 0.9× 88 3.2k

Countries citing papers authored by Alfredo Addeo

Since Specialization
Citations

This map shows the geographic impact of Alfredo Addeo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfredo Addeo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfredo Addeo more than expected).

Fields of papers citing papers by Alfredo Addeo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alfredo Addeo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfredo Addeo. The network helps show where Alfredo Addeo may publish in the future.

Co-authorship network of co-authors of Alfredo Addeo

This figure shows the co-authorship network connecting the top 25 collaborators of Alfredo Addeo. A scholar is included among the top collaborators of Alfredo Addeo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfredo Addeo. Alfredo Addeo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Imbimbo, Martina, Maxime Borgeaud, Margaret Ottaviano, et al.. (2025). Thymic epithelial tumors: what’s new and what’s next?. 4. 100024–100024. 1 indexed citations
2.
Lai, Eleonora, et al.. (2025). Liquid biopsy: An innovative tool in oncology. Where do we stand?. Seminars in Oncology. 52(2). 152343–152343. 2 indexed citations
3.
Jiménez-Pastor, Ana, Glen J. Weiss, Luis Martí‐Bonmatí, et al.. (2025). Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods. European Radiology. 36(3). 2157–2185.
4.
Luan, Kun, Alfredo Addeo, Raja M. Flores, Nobuhiko Seki, & Ao Liu. (2024). The value of high-risk clinicopathologic features for chemotherapy in stage I non-small cell lung cancer: a propensity score-matched study. Journal of Thoracic Disease. 16(3). 2125–2141. 4 indexed citations
5.
Addeo, Alfredo & Stephen V. Liu. (2024). ADRIATIC: When face value is enough. Med. 5(11). 1348–1350. 1 indexed citations
6.
Borgeaud, Maxime, et al.. (2024). Management of stage III non-small-cell lung cancer: rays of hope. SHILAP Revista de lepidopterología. 5(1). 85–95. 3 indexed citations
7.
Borgeaud, Maxime, Kaushal Parikh, Giuseppe Luigi Banna, et al.. (2024). Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review. Journal of Thoracic Oncology. 19(7). 973–983. 27 indexed citations
8.
Moraes, Francisco Cézar Aquino de, Ludimila Cavalcante, Yu Fujiwara, et al.. (2024). Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.. Journal of Clinical Oncology. 42(16_suppl). 8642–8642. 2 indexed citations
9.
Fujiwara, Yu, Francisco Cézar Aquino de Moraes, Natasha B. Leighl, et al.. (2024). Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis. JCO Precision Oncology. 8(8). e2400331–e2400331. 4 indexed citations
10.
11.
Mohr, Peter, Paolo A. Ascierto, Alfredo Addeo, et al.. (2024). Electronic patient-reported outcomes, fever management, and symptom prediction among patients with BRAF V600 mutant stage III–IV melanoma: The Kaiku Health platform. SHILAP Revista de lepidopterología. 2. 100254–100254. 1 indexed citations
12.
13.
Lijnsvelt, J., Sanna Iivanainen, Maria Grazia Vitale, et al.. (2023). CN3 Patient adherence to digital patient-reported outcome monitoring (PROM) in cancer immunotherapies. Annals of Oncology. 34. S1226–S1227.
14.
15.
16.
Addeo, Alfredo, et al.. (2023). An Optimized Method to Culture Human Primary Lung Tumor Cell Spheroids. Cancers. 15(23). 5576–5576. 1 indexed citations
17.
Tagliamento, Marco, Elisa Agostinetto, Roberto Borea, et al.. (2021). VISTA: A Promising Target for Cancer Immunotherapy?. SHILAP Revista de lepidopterología. Volume 10. 185–200. 41 indexed citations
18.
Addeo, Alfredo, Alex Friedlaender, Giuseppe Luigi Banna, & Glen J. Weiss. (2021). TMB or not TMB as a biomarker: That is the question. Critical Reviews in Oncology/Hematology. 163. 103374–103374. 154 indexed citations
19.
Pappot, Helle, Sandrine Aspeslagh, Anne Rogiers, et al.. (2021). Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study. European Journal of Cancer. 157. 225–237. 16 indexed citations
20.
Wargon, Victoria, et al.. (2012). エストロゲン受容体αは,サイクリンD1/MYCプロモーターにおいてプロゲステロン受容体と相互作用することにより,プロゲスチン誘発乳房腫瘍増殖を媒介する. Cancer Research. 72(9). 2416–2427. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Renato Martins Breakdown of academic impact, for papers by Ishmael Jaiyesimi Breakdown of academic impact, for papers by Raghav Sundar Breakdown of academic impact, for papers by Darragh Halpenny Breakdown of academic impact, for papers by Bhawna Sirohi Breakdown of academic impact, for papers by Alan H. Bryce Breakdown of academic impact, for papers by Yuanyuan Zhao Breakdown of academic impact, for papers by Kerry L. Reynolds Breakdown of academic impact, for papers by Sercan Aksoy Breakdown of academic impact, for papers by Bruno V. Sinn
Rankless by CCL
2026